Exposure-Response Analysis of Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

被引：0
|
作者：
Agarwal, Suresh [1 ]
Gopalakrishnan, Sathej [1 ]
Mensing, Sven [1 ]
Potluri, Jalaja [1 ]
Hayslip, John [1 ]
Friedel, Anna [1 ]
Menon, Rajeev [1 ]
Salem, Ahmed Hamed [1 ]
机构：
[1] AbbVie Inc, N Chicago, IL USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-116790
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5239
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis
    Agarwal, Suresh
    Gopalakrishnan, Sathej
    Mensing, Sven
    Potluri, Jalaja
    Hayslip, John
    Kirschbrown, Whitney
    Friedel, Anna
    Menon, Rajeev
    Salem, Ahmed Flamed
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (04) : 464 - 473
  • [2] Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
    Graveno, Molly E.
    Carulli, Alison
    Freyer, Craig W.
    Mangan, Brendan L.
    Nietupski, Robert
    Loren, Alison W.
    Frey, Noelle, V
    Porter, David L.
    Gill, Saar, I
    Hexner, Elizabeth O.
    Luger, Selina M.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Perl, Alexander E.
    Babushok, Daria, V
    Pratz, Keith W.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1645 - 1650
  • [3] Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
    Ferrara, Felicetto
    BLOOD CANCER JOURNAL, 2020, 10 (01)
  • [4] Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
    Felicetto Ferrara
    Blood Cancer Journal, 10
  • [5] Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia
    Ramakrishnan, Ramya
    Munir, Faryal
    Quesada, Andres Ernesto
    Hitzler, Johann
    Cuglievan, Branko
    PEDIATRIC BLOOD & CANCER, 2024, 71 (06)
  • [6] Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
    Piccini, Matteo
    Pilerci, Sofia
    Scappini, Barbara
    Mannelli, Francesco
    Ciolli, Gaia
    Pasquini, Andrea
    Fasano, Laura
    Quinti, Elisa
    Guglielmelli, Paola
    Mannarelli, Carmela
    Pancani, Fabiana
    Zizza, Michela
    Signori, Leonardo
    Vannucchi, Alessandro M.
    Gianfaldoni, Giacomo
    BLOOD, 2022, 140 : 9008 - 9009
  • [7] Venetoclax with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting
    Piccini, Matteo
    Pilerci, Sofia
    Scappini, Barbara
    Bencini, Sara
    Peruzzi, Benedetta
    Caporale, Roberto
    Signori, Leonardo
    Fabiana, Pancani
    Maria, Vannucchi Alessandro
    Gianfaldoni, Giacomo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S289 - S289
  • [8] Comparison of DNA hypomethylating agents and low dose cytarabine in elderly acute myeloid leukemia patients: A meta-analysis.
    Vincelette, Nicole
    Yun, Seongseok
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia
    Chyla, Brenda
    Popovic, Relja
    Potluri, Jalaja
    Hayslip, John
    Huang, Xin
    Zhu, Ming
    Mabry, Mack
    Bhathena, Anahita
    BLOOD, 2016, 128 (22)
  • [10] Sequential Venetoclax and FLT3 Inhibitors in Combination With Hypomethylating Agents or Low-Dose Chemotherapy in Newly Diagnosed, Unfit, FLT3-Mutant Acute Myeloid Leukemia Patients
    Al Mahmasani, Layal
    Moukalled, Nour
    El Cheikh, Jean
    Bazarbachi, Ali
    Abou Dalle, Iman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S228 - S228
12345